Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Slides:



Advertisements
Similar presentations
Follicular Lymphoma Transformed Lymphoma Diffuse Large B-Cell Lymphoma
Advertisements

Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.
13th Annual Hematology & Breast Cancer Update Update in Lymphoma
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.
A Pilot Study of PLX3397, a Selective Colony-Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitor, in Pigmented Villonodular Synovitis (PVNS) Presented.
Playing with Friends. During my breaks, sometimes I like to go to the playground.
Presented By Raymond Huang at 2014 ASCO Annual Meeting
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.
A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy Presented By Eudocia Lee at 2014.
Factor trees.
Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.
Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.
Highlights of the Day: LYMPHOMA Presented By Sonali Smith at 2014 ASCO Annual Meeting.
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS , ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.
Genes and Function: The Rewriting of our Textbooks of Pathology Presented By David Hafler at 2014 ASCO Annual Meeting.
Slide 1 Presented By Edward Neuwelt at 2014 ASCO Annual Meeting.
Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.
The Role of mTOR in Cancer Etiology and Treatment Based on presentations from the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting
Slide 1 Presented By Pierre-Yves Dietrich at 2014 ASCO Annual Meeting.
Immediate vs. deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study Presented.
Overview of the Disclosure part of the Appointments Process Update for Leaders, Managers, Secretaries and Administrators in Scotland.
Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.
Highlights of the Day III Genitourinary (Nonprostate) Cancer Presented By Toni Choueiri at 2014 ASCO Annual Meeting.
Slide 1 Presented By Jan Buckner at 2014 ASCO Annual Meeting.
Return to Home! Go To Next Slide! Return to Home! Go To Next Slide!
Presented By Michael Overman at 2016 ASCO Annual Meeting
A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (Moga) vs Investigator’s Choice (IC) in the Treatment of Patients.
Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or.
Presented By Shin Fujita at 2016 ASCO Annual Meeting
Test slide upload.
Piero Belforte 1995: CSELT THRIS SLIDES
Presented By Michele Cavo at 2016 ASCO Annual Meeting
Presented By Sham Mailankody at 2016 ASCO Annual Meeting
Presented By Lorenz Trumper at 2016 ASCO Annual Meeting
Securing the cure in resectable lung cancer
Presented By Mette Van Ramshorst at 2017 ASCO Annual Meeting
Highlights: Myeloma Oral Session
Presented By Antoni Ribas at 2014 ASCO Annual Meeting
Copyright © 2006 American Medical Association. All rights reserved.
Presented By Luca Malorni at 2017 ASCO Annual Meeting
continued on next slide
Presented By Amrita Krishnan at 2016 ASCO Annual Meeting
Sample Presentation. Slide 1 Info Slide 2 Info.
Presentation Test. Second Slide Third Slide It worked.
                                                                                                                                                                                                                                                
Innovations and Issues in Mantle Cell Lymphoma
continued on next slide
continued on next slide
Presented By James Rubenstein at 2016 ASCO Annual Meeting
by James O. Armitage, and Dan L. Longo
سياسة الإفصاح والشفافية ببنك التنمية الصناعية
DIGITAL COUNTDOWN WATCH - 5 MIN
Salles GA et al. Proc ASCO 2010;Abstract 8004.
Presented By Praful Ravi at 2016 ASCO Annual Meeting
UK Renal Registry 13th Annual Report
Presented By Steven Park at 2016 ASCO Annual Meeting
Webcast slides presentation
АВЛИГАТАЙ ТЭМЦЭХ ҮНДЭСНИЙ ХӨТӨЛБӨР /танилцуулга/
Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting
continued on next slide
Presented By Joshua Richter at 2016 ASCO Annual Meeting
NOAH: pCR Results Patients (%) P=0.002 P=0.003 P=0.29 P=0.43 With T
Presented By Andrew Evens at 2016 ASCO Annual Meeting
Treatment Initiation and Selection in Newly Diagnosed CLL
continued on next slide
Presentation transcript:

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 1 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Disclosures Mathias Rummel Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 3 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 4 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

B-R + Watch & Wait vs. B-R + 2 years Rituximab Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 6 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Patient disposition Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 8 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 9 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 10 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 11 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 12 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 13 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 14 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 15 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 16 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 17 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 18 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 19 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 20 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 21 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 22 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 23 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 24 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 25 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 26 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 27 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 28 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 29 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 30 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 31 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 32 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 33 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 34 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 35 Presented By Mathias Rummel at 2016 ASCO Annual Meeting

Presented By Mathias Rummel at 2016 ASCO Annual Meeting Slide 36 Presented By Mathias Rummel at 2016 ASCO Annual Meeting